Trial · NCT04474938
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hematologic very good partial response or better at 3 months after treatment initiation | 3 months | Very good partial response or better is defined as complete response or very good partial response. Complete response: normalization of free light chain levels and ratio with negative serum and urine immunofixation electrophoresis. Very good partial response: difference between involved and uninvolved free light chains (dFLC) less than 40 mg/L |
| Secondary | Overall survival | 2 years | |
| Secondary | major organ deterioration progression-free survival | 2 years | |
| Secondary | Time to next treatment | 2 years | |
| Secondary | Mortality within 1 month from treatment initiation | 1 month | |
| Secondary | Mortality within 3 months from treatment initiation | 3 months | |
| Secondary | Mortality within 6 months from treatment initiation | 6 months | |
| Secondary | Hematologic very good partial response or better at 1 month after treatment initiation | 1 month | |
| Secondary | Hematologic very good partial response or better at 6 months after treatment initiation | 6 months | |
| Secondary | Hematologic very good partial response or better at 12 months after treatment initiation | 12 months | |
| Secondary | Stringent dFLC response | 1 year | dFLC declined to less than 10 mg/L |
| Secondary | Time to hematologic response | 1 year | |
| Secondary | Organ response at 3 months after treatment initiation | 3 months | |
| Secondary | Organ response at 6 months after treatment initiation | 6 months | |
| Secondary | Organ response at 12 months after treatment initiation | 12 months | |
| Secondary | Time to cardiac response | 1 year | |
| Secondary | Time to liver response | 1 year | |
| Secondary | Time to renal response | 1 year | |
| Secondary | Adverse events | treatment initiation to 30 days after last dose of treatment | Adverse events are collected until 30 days after last dose of treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04474938/registered